Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.62 |
| ▸ | CTSG | P08311 | 1/20 | 0.62 |
| ▸ | CMA1 | P23946 | 1/20 | 0.62 |
| ▸ | CTRC | Q99895 | 1/20 | 0.62 |
| ▸ | EP300 | Q09472 | 8/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13793073 | 0.82 | ELANE (0.82) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL10159022 | 0.81 | EP300 (0.80) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL20673341 | 0.76 | F2 (0.64) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL14560433 | 0.76 | ELANE (0.58) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL23440029 | 0.74 | F2 (0.60) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL18632024 | 0.74 | EP300 (1.00) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL14560436 | 0.73 | KMT2A (0.59) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL10159033 | 0.73 | EP300 (0.57) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL14870544 | 0.72 | ALDH1A1 (0.62) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL10158966 | 0.72 | EP300 (0.63) | ELANEF2PLGCTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499494-B2 | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2015-07-23 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | ELANE 3441/4885F2 2484/4885PLG 1936/4885 |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | ELANE 3441/4885F2 2484/4885PLG 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.